Qiagen (NYSE:QGEN – Get Free Report) issued an update on its FY 2024 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 2.100- for the period, compared to the consensus estimate of 2.110. The company issued revenue guidance of $2.0 billion-, compared to the consensus revenue estimate of $2.0 billion. Qiagen also updated its FY24 guidance to at least $2.10 EPS.
Qiagen Trading Down 1.0 %
Shares of NYSE QGEN traded down $0.41 during trading on Thursday, hitting $42.40. 403,784 shares of the company traded hands, compared to its average volume of 1,217,944. The company has a 50-day moving average price of $42.56 and a 200-day moving average price of $42.71. The company has a quick ratio of 1.62, a current ratio of 1.99 and a debt-to-equity ratio of 0.24. Qiagen has a 1 year low of $34.74 and a 1 year high of $47.70. The firm has a market capitalization of $9.68 billion, a P/E ratio of 28.71, a P/E/G ratio of 3.58 and a beta of 0.42.
Qiagen (NYSE:QGEN – Get Free Report) last issued its earnings results on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. The business had revenue of $459.00 million for the quarter, compared to analyst estimates of $453.91 million. Qiagen had a net margin of 17.38% and a return on equity of 12.50%. The company’s revenue for the quarter was down 5.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.53 EPS. On average, equities analysts predict that Qiagen will post 2.09 EPS for the current year.
Analyst Ratings Changes
Read Our Latest Analysis on Qiagen
Qiagen Company Profile
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Further Reading
- Five stocks we like better than Qiagen
- Earnings Per Share Calculator: How to Calculate EPS
- Meta Stock: 3 Reasons This Stumble Is a Golden Buying Opportunity
- 3 Stocks to Consider Buying in October
- 3 Staples Stocks to Cushion Lower Consumer Sentiment
- Investing in Construction Stocks
- Zillow’s Earnings Dip: An Opportunity for Visionaries
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.